Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

To determine the recommended phase 2 dose (RP2D) of the combination of neratinib and sodium valproate when given to patients with advanced solid tumors. Then to explore the antitumor effects of the neratinib and sodium valproate combination in advanced solid tumors with attention to RAS-mutated tumors, EGFR-altered GBM, and ocular melanoma, as part of the phase 2 expansion cohort.

Trial Details

NCT ID
NCT03919292
Phase
PHASE1 / PHASE2
Sponsor
Virginia Commonwealth University
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Neratinib
  • Divalproex Sodium
Locations (sample)
  • Richmond, Virginia, United States|37.55376,-77.46026

Key Eligibility Criteria

  • Phase 1 - Dose Escalation Phase: Advanced solid tumor that has progressed during or after treatment with approved therapies or for which there is n…
  • Phase 2 - Dose Expansion Phase: One of the following advanced solid tumors that is RAS-mutated and has progressed during or after treatment with at…
  • Colon Cancer with a RAS mutation
  • Pancreatic Cancer with a RAS mutation

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →